However, it has also been shown that high doses of VEFG inhibitors in combination with PD-1/PD-L1 inhibitors can directly disrupt tumor vasculature, which can lead to more severe hypoxia and thus exacerbate tumor progression (148). The gene discussed is CD274; the disease is neoplasm.